BioInvent International AB has further extended the research term under its cancer immunotherapy research collaboration and license agreement with Pfizer Inc. until the end of 2020. In December 2016, the companies entered an agreement for the development and commercialization of antibodies targeting tumor-associated myeloid cells discovered using BioInvent’s proprietary F.I.R.S.T drug discovery platform. The research extension allows the companies to further identify and characterize n...